There are currently no events to display.

Recent News

Date Title and Summary
Toggle Summary ViewRay® to Participate in Upcoming Conferences
CLEVELAND , Nov. 21, 2017 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chris Raanes , Chief Executive Officer, and Ajay Bansal , Chief Financial Officer are scheduled to participate in two upcoming investor conferences. The first conference is the 29th Annual Piper Jaffray
Toggle Summary ViewRay Reports Third Quarter 2017 Financial Results
Strong Order Momentum in Q3, continuing in Q4 CLEVELAND , Nov. 13, 2017 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the third quarter and nine months ended September 30, 2017 . Third Quarter & Recent Financial Highlights: Total revenue of $12.2 million in Q3
Toggle Summary Washington University Completes Installation of Second MRIdian MR-Guided Radiotherapy System from ViewRay
Greater Assurance in Tumor Targeting Drives Expansion of MR-Guided Radiation Therapy Program CLEVELAND , Nov. 10, 2017 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St.
Toggle Summary ViewRay® to Present at the Stifel 2017 Healthcare Conference
CLEVELAND , Nov. 9, 2017 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY ) announced today that Chris Raanes , Chief Executive Officer, and Ajay Bansal , Chief Financial Officer are scheduled to present at the Stifel 2017 Healthcare Conference. Event:           Stifel 2017 Healthcare Conference Date: 

Corporate Profile

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first and only MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian® addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian®’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian® will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Featured Items

Upcoming Events

There are currently no events to display.

Stock Quote

Event Calendar more >

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!

Click here for E-mail Alerts

Copyright Nasdaq. Minimum 15 minutes delayed.

Copyright 2017 © ViewRay. All rights reserved